DS
RGNX icon

David Shaw’s Regenxbio RGNX Stock Holding History

David Shaw’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.54M Buy
712,814
+426,813
+149% +$3.54M ﹤0.01% 1964
2026
Q1 		$2.4M Buy
286,001
+217,613
+318% +$2.29M ﹤0.01% 2777
2025
Q4 		$985K Buy
+68,388
New +$852K ﹤0.01% 3558
2025
Q1 		– Sell
-63,377
Closed -$490K – 4657
2024
Q4 		$490K Buy
63,377
+8,271
+15% +$77.7K ﹤0.01% 3631
2024
Q3 		$578K Sell
55,106
-87,563
-61% -$1.07M ﹤0.01% 3616
2024
Q2 		$1.67M Sell
142,669
-13,491
-9% -$210K ﹤0.01% 2820
2024
Q1 		$3.29M Sell
156,160
-1,480
-0.9% -$26.3K ﹤0.01% 2237
2023
Q4 		$2.83M Buy
157,640
+113,012
+253% +$1.99M ﹤0.01% 2395
2023
Q3 		$735K Buy
+44,628
New +$809K ﹤0.01% 3249
2023
Q1 		– Sell
-12,249
Closed -$278K – 4791
2022
Q4 		$278K Sell
12,249
-4,200
-26% -$94.9K ﹤0.01% 4118
2022
Q3 		$435K Buy
+16,449
New +$488K ﹤0.01% 4119
2021
Q4 		– Sell
-60,303
Closed -$2.53M – 5664
2021
Q3 		$2.53M Sell
60,303
-201,467
-77% -$7.25M ﹤0.01% 2814
2021
Q2 		$10.2M Buy
261,770
+5,545
+2% +$198K 0.01% 1480
2021
Q1 		$8.74M Buy
256,225
+110,838
+76% +$4.73M 0.01% 1450
2020
Q4 		$6.59M Buy
145,387
+9,908
+7% +$346K 0.01% 1665
2020
Q3 		$3.73M Buy
135,479
+28,398
+27% +$926K ﹤0.01% 1912
2020
Q2 		$3.94M Buy
107,081
+14,918
+16% +$556K ﹤0.01% 1843
2020
Q1 		$2.98M Buy
92,163
+68,402
+288% +$2.85M ﹤0.01% 1862
2019
Q4 		$973K Sell
23,761
-11,514
-33% -$455K ﹤0.01% 3006
2019
Q3 		$1.26M Sell
35,275
-9,125
-21% -$370K ﹤0.01% 2697
2019
Q2 		$2.28M Buy
+44,400
New +$2.22M ﹤0.01% 2151
2017
Q4 		– Sell
-9,516
Closed -$314K – 3713
2017
Q3 		$314K Buy
+9,516
New +$214K ﹤0.01% 3124
2016
Q1 		– Sell
-29,907
Closed -$496K – 3721
2015
Q4 		$496K Buy
+29,907
New +$594K ﹤0.01% 3098

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

David Shaw's RGNX Position: Q2 2026 in Review

David Shaw increased its Regenxbio (RGNX) stake by 149% in Q2 2026, buying an estimated $3.54M and bringing the position to 712,814 shares worth $8.54M. The position accounts for ﹤0.01% of the portfolio, ranked #1964.

David Shaw first reported a position in RGNX in Q4 2015 and has held it in 23 quarters since. The position peaked at $10.2M in Q2 2021. 164 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.

  • David Shaw held 712,814 shares of Regenxbio worth $8.54M as of Q2 2026.
  • David Shaw bought 426,813 Regenxbio shares in Q2 2026, an estimated $3.54M.
  • Regenxbio made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #1964 holding.
  • David Shaw first reported a position in Regenxbio in Q4 2015 and has held it in 23 quarters since.
  • David Shaw's Regenxbio position peaked at $10.2M in Q2 2021.
  • 164 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.